Year: 2026

Press release Communiqué de presseRegulated Syensqo releases its 2025 Annual Integrated Report Brussels, Belgium – March 31, 2026 – 08:30 CEST Syensqo has published its 2025 Annual Integrated Report today. The report comprises the company’s financial and sustainability statements, compliant with the EU Corporate Sustainability Reporting Directive (CSRD), and One Planet roadmap progress. The 2025 annual integrated report is posted in the Financials and Sustainability Sections of the Syensqo website. A European Single Electronic Format (ESEF) as required by EU Regulation 2019/815 is also available for download. Full press release available here. About Syensqo Syensqo is a science company developing groundbreaking solutions that enhance the way we live, work, travel and play. Inspired by the scientific councils which Ernest Solvay...

Press release31 March 2026 at 9.30AM On March 31, 2026, Moody’s Ratings has assigned eQ Community Properties Fund IG (investment grade) Baa3 rating with a stable outlook. This marks the first time a Nordic property fund has received a rating from a global rating agency. The rating reflects eQ Community Properties Fund’s position as the largest private investor of social infrastructure properties in Finland. The size of the fund is EUR 1.7 billion and it is the largest property fund in Finland. Rating also reflects fund’s strong geographic concentration in the Helsinki capital region (nearly 60 % of portfolio value) and major urban growth centres as well as stable operating performance supported by long-term, index-linked rental income. Approximately 65% of rental income is derived directly from public sector tenants.A public rating...

Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this year LONDON and PHILADELPHIA, March 31, 2026 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce today, that the first patient has been treated in the FOCUS-01 trial, the multicenter, open-label Phase 1 clinical trial of FAP-Exd (AVA6103) in adults with selected advanced cancers. Avacta has very recently announced a £10 million fundraise by way of an oversubscribed placing and subscription to extend the Company’s cash runway into early Q1 2027, expected to provide sufficient funding beyond the...

EliteSiC technology boosts efficiency, power density and long-term reliability for Sineng’s high-power energy storage and solar inverter solutions Summary onsemi announced a new design win with Sineng Electric, which will feature onsemi’s latest‑generation hybrid power integrated module (PIM) in two utility‑scale renewable energy platforms. The PIM features onsemi’s FS7 insulated‑gate bipolar transistor (IGBT) and EliteSiC technology and will be used in Sineng’s next‑generation 430 kW liquid‑cooled energy storage systems (ESS) and 320 kW utility‑scale solar string inverter. Using onsemi’s technology, the Sineng solutions will deliver improved efficiency, higher power density, lower switching losses and improved thermal performance, advancing performance standards in utility-scale renewable energy applications. In benchmark testing against...

Status update on the project to adapt and strengthen the Casino Group’s financial structure Paris, 31 March 2026 Further to the Casino Group’s previous communications regarding the project to adapt and strengthen its financial structure, and in particular the publication of the proposals dated 16 March 20261, the Group announces that the key terms of the new proposals, as formulated to date, are set out in a presentation published today on its website (link). It is specified that all inside information relating to Casino Group that may have been disclosed to date by Casino to the various stakeholders subject to confidentiality agreements has been made public. The Group recalls that should such a transaction to adapt and strengthen the financial structure be completed, it would result in significant dilution for existing shareholders....

TomTom selected by LOCUS to provide high-precision traffic data for location intelligence platformTomTom selected by LOCUS to provide high-precision traffic data for location intelligence platformAMSTERDAM, The Netherlands, March 31, 2026 (GLOBE NEWSWIRE) — TomTom (TOM2), the specialist in mapping and location technology, today announced a partnership with LOCUS, a mobility analytics and location intelligence company, to integrate TomTom Traffic into the LOCUS platform. The integration of TomTom’s advanced traffic data with LOCUS’ analytical and modeling suite will strengthen outcomes for public and private sector customers, supporting the creation of smarter cities, optimized mobility networks, digital twins, and more resilient communities across North America. This integrated solution addresses the growing demand for...

BASEL, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) —BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases. BioVersys joins forces with Hackensack Meridian Health (HMH) and their Center for Discovery and Innovation (CDI) to advance ansamycin antimicrobial candidates through an exclusive collaboration and license agreement. HMH is a leading US not-for-profit health care network, and the largest in New Jersey. NTMs are ubiquitous environmental bacteria, predominately causing morbidity and death in those with long-term lung conditions, like bronchiectasis or cystic fibrosis and requiring long-term antibiotic combination treatments.BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development...

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host diseaseRezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment optionsParis, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at least 40 kg. The medicine is to be used when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted. The conditional marketing authorisation is contingent on completion of a confirmatory, randomised, controlled study. This follows the positive opinion by the European Medicines Agency’s...